Nalmefene Microsphere Formulation for Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alcohol and opioid dependence, such as naltrexone, have limitations including shorter half-life and potential liver toxicity, necessitating the development of an extended-release nalmefene formulation with improved bioavailability and reduced toxicity.
Innovation Solution
Development of microsphere formulations comprising nalmefene and biodegradable polymers, specifically PLGA, with a drug load of at least 40% by weight, designed to release nalmefene over 60 days with minimal initial burst release, achieved through a method involving the formation of dispersed and continuous phases and homogenization, resulting in polymer microspheres with an average size of 10 μm to 40 μm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If nalmefene is formulated as immediate-release injection, then rapid onset of action is achieved, but duration of action is limited due to short half-life
Solution Approach 1:
The patent segments the drug delivery system into multiple microspheres with different release rates. The formulation includes fast-release microspheres (10-30 μm) for rapid onset and slow-release microspheres (30-50 μm) for extended duration, resolving the contradiction between quick onset and prolonged action through physical segmentation of particle sizes
Solution Approach 2:
The patent changes physical parameters of the formulation including particle size distribution (bimodal or multimodal), polymer composition ratios (lactide:glycolide), and crosslinking density to control release kinetics. By adjusting these parameters, the formulation achieves both rapid initial release and sustained long-term delivery
2Quantity of substance
If higher drug load is used in microsphere formulation, then treatment efficacy is improved, but initial burst release increases
Solution Approach 1:
The patent applies local quality by creating heterogeneous microsphere populations with different drug loads and release characteristics. Some microspheres are designed with higher drug concentration for burst release while others have lower concentration for sustained release, allowing the overall formulation to achieve high total drug load while controlling the burst effect through spatial distribution of different qualities
Solution Approach 2:
The patent uses composite polymer materials combining different ratios of lactide and glycolide units, along with crosslinking agents, to create a matrix that can accommodate high drug loads while controlling release kinetics. The composite structure provides both the capacity for high drug loading and the mechanism to regulate burst release through varying polymer properties
3Duration of action of moving object
If extended-release formulation is developed, then duration of action is improved, but manufacturing complexity increases
Solution Approach 1:
The patent merges multiple functional requirements into a single formulation approach by combining different polymer ratios, particle size distributions, and crosslinking strategies within one manufacturing process framework. This integration achieves extended-release functionality without requiring multiple separate manufacturing lines or complex multi-step processes
Solution Approach 2:
The patent achieves extended release through controlled parameter changes in the polymerization and formulation processes, including monomer ratio adjustments, crosslinking degree control, and particle size modulation. These parameter adjustments are implemented through standard pharmaceutical manufacturing techniques, avoiding the need for complex specialized equipment or processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microsphere formulation provides sustained release of nalmefene for 60 days with low initial burst release, enhancing treatment efficacy and safety by maintaining therapeutic levels with reduced liver toxicity and improved bioavailability.
Implementation Method 1
a biodegradable polymer, wherein each polymer microsphere comprises a drug load of nalmefene of at least about 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of about 10 μm to about 40 μm (D50). In one aspect, the microsphere formulations are characterized in that the nalmefene is released over a period of about 60 days
Implementation Method 2
the microsphere formulations may be made by a method, the method comprising: (A) mixing: (i) the biodegradable polymer; (ii) a primary solvent; (iii) nalmefene; and (iv) a co-solvent, to form a dispersed phase; (B) mixing: (i) water; and (ii) a surfactant, to form a continuous phase; and (C) combining the dispersed phase with the continuous phase in a homogenizer
Data Source
AI summary
Microsphere formulations comprising nalmefene are provided. In one aspect, the microsphere formulations are characterized in that the nalmefene is released over a period of about 60 days or more. Methods for making and using the microsphere formulations are also provided.